Patient outcome in primary myelofibrosis (PMF) is significantly influenced by karyotype. We studied 879 PMF patients to determine the individual and combinatorial prognostic relevance of somatic mutations. Analysis was performed in 483 European patients and the seminal observations were validated in 396 Mayo Clinic patients. Samples from the European cohort, collected at time of diagnosis, were analyzed for mutations in ASXL1, SRSF2, EZH2, TET2, DNMT3A, CBL, IDH1, IDH2, MPL and JAK2. Of these, ASXL1, SRSF2 and EZH2 mutations inter-independently predicted shortened survival. However, only ASXL1 mutations (HR: 2.02; P<0.001) remained significant in the context of the International Prognostic Scoring System (IPSS). These observations were validated in the Mayo Clinic cohort where mutation and survival analyses were performed from time of referral. ASXL1, SRSF2 and EZH2 mutations were independently associated with poor survival, but only ASXL1 mutations held their prognostic relevance (HR: 1.4; P=0.04) independent of the Dynamic IPSS (DIPSS)-plus model, which incorporates cytogenetic risk. In the European cohort, leukemia-free survival was negatively affected by IDH1/2, SRSF2 and ASXL1 mutations and in the Mayo cohort by IDH1 and SRSF2 mutations. Mutational profiling for ASXL1, EZH2, SRSF2 and IDH identifies PMF patients who are at risk for premature death or leukemic transformation.

Mutations and prognosis in primary myelofibrosis / Vannucchi, Am; Lasho, Tl; Guglielmelli, P; Biamonte, F; Pardanani, A; Pereira, A; Finke, C; Score, J; Gangat, N; Mannarelli, C; Ketterling, Rp; Rotunno, G; Knudson, Ra; Susini, Mc; Laborde, Rr; Spolverini, A; Pancrazzi, A; Pieri, L; Manfredini, Rossella; Tagliafico, Enrico; Zini, Roberta; Jones, A; Zoi, K; Reiter, A; Duncombe, A; Pietra, D; Rumi, E; Cervantes, F; Barosi, G; Cazzola, M; Cross, Nc; Tefferi, A.. - In: LEUKEMIA. - ISSN 0887-6924. - STAMPA. - 27:9(2013), pp. 1861-1869. [10.1038/leu.2013.119]

Mutations and prognosis in primary myelofibrosis

MANFREDINI, Rossella;TAGLIAFICO, Enrico;ZINI, Roberta;
2013

Abstract

Patient outcome in primary myelofibrosis (PMF) is significantly influenced by karyotype. We studied 879 PMF patients to determine the individual and combinatorial prognostic relevance of somatic mutations. Analysis was performed in 483 European patients and the seminal observations were validated in 396 Mayo Clinic patients. Samples from the European cohort, collected at time of diagnosis, were analyzed for mutations in ASXL1, SRSF2, EZH2, TET2, DNMT3A, CBL, IDH1, IDH2, MPL and JAK2. Of these, ASXL1, SRSF2 and EZH2 mutations inter-independently predicted shortened survival. However, only ASXL1 mutations (HR: 2.02; P<0.001) remained significant in the context of the International Prognostic Scoring System (IPSS). These observations were validated in the Mayo Clinic cohort where mutation and survival analyses were performed from time of referral. ASXL1, SRSF2 and EZH2 mutations were independently associated with poor survival, but only ASXL1 mutations held their prognostic relevance (HR: 1.4; P=0.04) independent of the Dynamic IPSS (DIPSS)-plus model, which incorporates cytogenetic risk. In the European cohort, leukemia-free survival was negatively affected by IDH1/2, SRSF2 and ASXL1 mutations and in the Mayo cohort by IDH1 and SRSF2 mutations. Mutational profiling for ASXL1, EZH2, SRSF2 and IDH identifies PMF patients who are at risk for premature death or leukemic transformation.
2013
27
9
1861
1869
Mutations and prognosis in primary myelofibrosis / Vannucchi, Am; Lasho, Tl; Guglielmelli, P; Biamonte, F; Pardanani, A; Pereira, A; Finke, C; Score, J; Gangat, N; Mannarelli, C; Ketterling, Rp; Rotunno, G; Knudson, Ra; Susini, Mc; Laborde, Rr; Spolverini, A; Pancrazzi, A; Pieri, L; Manfredini, Rossella; Tagliafico, Enrico; Zini, Roberta; Jones, A; Zoi, K; Reiter, A; Duncombe, A; Pietra, D; Rumi, E; Cervantes, F; Barosi, G; Cazzola, M; Cross, Nc; Tefferi, A.. - In: LEUKEMIA. - ISSN 0887-6924. - STAMPA. - 27:9(2013), pp. 1861-1869. [10.1038/leu.2013.119]
Vannucchi, Am; Lasho, Tl; Guglielmelli, P; Biamonte, F; Pardanani, A; Pereira, A; Finke, C; Score, J; Gangat, N; Mannarelli, C; Ketterling, Rp; Rotunn...espandi
File in questo prodotto:
File Dimensione Formato  
leukemia 2013.pdf

Solo gestori archivio

Tipologia: Versione pubblicata dall'editore
Dimensione 2.82 MB
Formato Adobe PDF
2.82 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/979705
Citazioni
  • ???jsp.display-item.citation.pmc??? 270
  • Scopus 636
  • ???jsp.display-item.citation.isi??? 595
social impact